insights_auto
Why is CGON down 4.21%?
Dive Deeperchevron_right
CGON:NASDAQ
CG Oncology Inc
$61.96
arrow_downward
-4.21%(-2.72) 1D
$61.96
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 2, 4:00:02 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CGON...
Open
$64.18
High
$64.68
Low
$61.01
Mkt. cap
5.49B
Avg. vol.
1.00M
Volume
1.28M
52-wk high
$80.97
52-wk low
$35.80
EPS
-$2.70
Shares outstanding
88.64M
No. of employees
142
Open
$64.18
High
$64.68
Low
$61.01
Mkt. cap
5.49B
Avg. vol.
1.00M
Volume
1.28M
52-wk high
$80.97
52-wk low
$35.80
EPS
-$2.70
Shares outstanding
88.64M
No. of employees
142
News stories
From web sources and news partners
Foreign Policy Journal
·
35 minutes ago
RTX Corporation's (NYSE: RTX) $271 Billion Backlog Fuels Analyst Optimism Despite Engine Concerns
Dealroom
·
39 minutes ago
Agility Robotics clears SPAC vote, expects $465M and Nasdaq debut November 5
investingLive
·
8 minutes ago
JPMorgan’s four midterm scenarios: S&P 500 seen moving between -0.25% and +1.25%
Bloomberg.com
·
4 hours ago
Nasdaq 100 Enters Correction as Megacap Results Amplify AI Fears
About CG Oncology Inc
CEO-
Employees142
Founded2010
HeadquartersDallas, Texas, United States
SectorBiotechnology
Websitecgoncology.com
Analyst ratings
Based on 11 analysts giving stock ratings to CGON in the past 3 months
Strong buy
Buy
11
Hold
0
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for CGON in the last 3 months.
Highest
Current $61.96
$108.00 (+74.31%)
Average
$92.30 (+48.97%)
Lowest
$79.00 (+27.50%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Unknown Analyst Guggenheim | Buy | Initiated | $90.00 | +45.3% | 10/21/2026 |
Gregory Renza Truist Financial | Buy | Maintained | - | - | 09/10/2026 |
David Dai UBS | Buy | Reiterated | $90.00 | +45.3% | 08/21/2026 |
Sean Laaman Morgan Stanley | Buy | Reiterated | $93.00 | +50.1% | 08/17/2026 |
Sam Slutsky LifeSci Capital | Buy | Maintained | $108.00 | +74.3% | 08/07/2026 |
Joshua Schimmer Cantor Fitzgerald | Buy | Reiterated | $105.00 | +69.5% | 08/06/2026 |
Kelsey Goodwin Piper Sandler | Buy | Reiterated | $85.00 | +37.2% | 08/07/2026 |
Leonid Timashev RBC Capital | Buy | Maintained | $79.00 | +27.5% | 08/06/2026 |
Alec Stranahan Bank of America Securities | Buy | Reiterated | $88.00 | +42% | 08/07/2026 |
Boris Peaker JonesTrading | Buy | Maintained | $85.00 | +37.2% | 08/06/2026 |
Andres Y. Maldonado H.C. Wainwright | Buy | Reiterated | $100.00 | +61.4% | 08/07/2026 |
Kalpit Patel Wolfe Research | Hold | Maintained | - | - | 05/26/2026 |
Robert Driscoll Wedbush | Buy | Reiterated | $80.00 | +29.1% | 05/18/2026 |
Brian Cheng J.P. Morgan | Buy | Reiterated | $96.00 | +54.9% | 05/11/2026 |
Tyler Van Buren TD Cowen | Buy | Maintained | - | - | 05/11/2026 |
Soumit Roy JonesTrading | Buy | Maintained | $85.00 | +37.2% | 04/06/2026 |
Bradley Canino Guggenheim | Buy | Reiterated | $90.00 | +45.3% | 02/27/2026 |
Next call in 10 days
Thu, Nov 12, 12:30 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / -$0.81
Revenue / Est. (USD)
- / 534.48K
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 1.67M | 2.32M | 1.08M | 1.16M |
Cost of goods sold | 29.46M | 33.03M | 46.69M | 58.58M |
Cost of revenue | 29.46M | 33.03M | 46.69M | 58.58M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 23.33M | 17.99M | 20.78M | 28.98M |
Operating expense | 23.33M | 17.99M | 20.78M | 28.98M |
Total operating expenses | 52.80M | 51.02M | 67.47M | 87.56M |
Operating income | -51.13M | -48.70M | -66.39M | -86.40M |
Other non operating income | -100.00K | -53.00K | -101.00K | 16.00K |
EBT including unusual items | -43.81M | -41.31M | -60.20M | -79.06M |
EBT excluding unusual items | -43.81M | -41.31M | -60.20M | -79.06M |
Income tax expense | - | - | - | - |
Effective tax rate | - | - | - | - |
Other operating expenses | - | - | - | - |
Net income | -43.81M | -41.31M | -60.20M | -79.06M |
Net profit margin | -2,629.53% | -1,779.03% | -5,558.82% | -6,832.84% |
Earnings per share | -0.57 | -0.51 | -0.71 | -0.90 |
Interest and investment income | 7.42M | 7.44M | 6.29M | 7.33M |
Interest expense | - | - | - | - |
Net interest expenses | 7.42M | 7.44M | 6.29M | 7.33M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -50.71M | -47.85M | -65.55M | -85.55M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events